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Cell electroporationNew polycationic peptides were designed on the basis of 16-mer and 14-mer fragments of the peptide
BTM-P1, derived from the Cry11Bb protoxin. The peptides caused mitochondrial, but not red blood cell mem-
brane permeabilization. Conjugation of the cell penetrating hepta-arginine vector to their N- or C-termini
through two glycine residues resulted in more active peptides, which also permeabilized the red blood
cells with a relatively high plasma membrane potential generated in the presence of valinomycin. The efﬁ-
ciency of the peptides was remarkably higher in the lower ionic strength media. The capability of the plasma
membrane permeabilization of the normal red blood cells by the designed conjugated peptides and by
known anticancer peptide R7-KLA was also strongly potentiated by the external electrical pulses applied to
the cell suspension. These results open the new avenues of the local destruction of solid tumors using the
combined “peptide-–electrical pulses” synergistic treatment. The designed peptides were active against the
human leukemia Jurkat cells but not against the normal wild type CHO cells.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Many natural polycationic amphipathic peptides with antimicrobial
activity have also been found to kill mammalian cancer cells [1–7].
Similarly, the artiﬁcial antimicrobial polycationic peptides enriched in
KLA sequences [8,9] have been shown to induce apoptosis in cultured
cancer cells and solid tumors [10–12].
The anticancer activity of the 14-residue peptide (KLAKLAK)2 has
been signiﬁcantly enhanced by its conjugation to a cancer-cell binding
peptide LTVSPWY [13], to a protein transduction domain PTD-5
[11,14], to a “tumor-homing” cyclic peptide CNGRCor double-cyclic pep-
tide ACDCRGDCFC [10], to a peptide CPIEDRPMC speciﬁcally detecting
HT29 colon carcinoma cells [15], to monoclonal antibodies recognizing
malignant hematopoietic cells [16], to an antibody of the prostate-
speciﬁcmembrane antigen [17], or to the hepta-arginine cell penetrating
peptide [12].
The peptide RRRRRRR-GG-KLAKLAKKLAKLAK (named as R7-KLA)
[12], formed by conjugation of the peptide (KLAKLAK)2 to the cell
penetrating hepta-arginine vector (R7) [18,19] through two additional
unstructured glycine residues, has demonstrated the activity against
cancer cells that was two orders of magnitude higher than that of thehenol; P7-27, IYLATALAKWALK
ALAKWALKQGF; P7-5, IYLATAL
AKWALKQ; P7-7, IYLATALAKW
K; KLA-R7, KLAKLAKKLAKLAK-
rights reserved.un-conjugated KLA peptide [12]. It has been assumed that the R7 frag-
ment increased cell delivery of the fragment (KLAKLAK)2 to speciﬁcally
target and damage mitochondria [12], because it has been demonstrat-
ed that 10 μM(KLAKLAK)2 decreased light dispersion in the suspension
of isolated rat liver mitochondria causing their swelling [10].
Further studies of the mechanism of action of R7-KLA peptide and
of its D-amino acid analog r7-kla, designed and synthesized in the
Massachusetts General Hospital of the Harvard Medical School, have
demonstrated that R7 fragments of these peptides increased not
only cell delivery of the peptides, as demonstrated in [12], but also re-
markably enhanced their capacity to directly permeabilize isolated
mitochondria [20]. Most importantly, a signiﬁcant increase in the per-
meabilization of the red blood cells (RBCs) by the peptides R7-KLA or
r7-kla was observed when a high plasma membrane potential (minus
inside) was artiﬁcially increased in the presence of valinomycin [20].
This phenomenon of potential-dependent permeabilization of mi-
tochondrial and plasma membranes has been earlier observed for the
peptide BTM-P1 [20–23] derived from the Cry11Bb protoxin. This
peptide has demonstrated more than one order of magnitude higher
membrane permeabilizing activity than R7-KLA or r7-kla [20]. It has
been observed that BTM-P1 at the concentration of 0.36 μM induced
fast oxidation of endogenous NAD(P)H, known to depend on the
inner membrane potential, and caused swelling of isolated mitochon-
dria [20]. Meanwhile, the peptide (klaklak)2, a fragment of the pep-
tide r7-kla [12], was inactive even at the concentration of 3.6 μM
[20]. These observations allowed us to hypothesize [24] that new an-
ticancer polycationic peptides might be designed on the basis of even
shorter fragments of highly active BTM-P1. Such Cry toxin fragments,
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the artiﬁcial peptides to conjugate them to cell penetrating vectors
or to “tumor-homing” fragments with the aim to obtain new peptides
with selective anticancer activity.
In the present work, we designed four polycationic peptides. Two
peptides were designed on the basis of the 16-mer fragment KYLAT
ALAKWALKQGF and the other two were designed on the basis of the
14-mer fragment KYLATALAKWALKQ of BTM-P1. These fragments
were slightly modiﬁed by replacing the ﬁrst N-terminus lysine residue
to isoleucine. The cell penetrating vector R7 was conjugated to each of
these modiﬁed fragments at their N- or C-termini through two glycine
residues, similar to that described by Law et al. for the peptide R7-KLA
[12]. The peptides demonstrated toxicity for human leukemia Jurkat
cells that was higher than that observed for the peptides R7-KLA or
KLA-R7. No measurable toxicity was detected in the case of the normal
wild type CHO cells. The designed peptides permeabilized isolated rat
liver mitochondria but did not induce hemolysis of the normal RBCs.
Remarkable permeabilization of the cell plasma membrane, due to the
formation of peptide pores,was observedwhen a relatively high plasma
membrane potential was artiﬁcially generated in the presence of
valinomycin, and this effect was even higher in the low ionic strength
media. The capability of permeabilization of the normal RBCs by the
peptides was also strongly potentiated by the application of external
electrical pulses. The electrical pulses alone did not cause a signiﬁcant
permeabilizing effect. The obtained results open the possibility of devel-
opment of novel “peptide–electrical pulses” synergistic technologies to
locally damage cancer tissues.
2. Materials and methods
2.1. Materials
The peptideswere designed in our laboratory on the basis of two rel-
atively short fragments KYLATALAKWALKQGF and KYLATALAKWALKQ
of BTM-P1 derived earlier from the Cry11Bb protoxin [21,22]. The ﬁrst
lysine residue of these fragments was replaced by the hydrophobic
isoleucine residue and the R7 cell-delivery vector was conjugated to
each of these fragments at the N- or C-terminus through two glycine
residues (Table 1). All peptideswere synthesized by GenScript Corpora-
tion (NJ, USA) according to our orders. For comparison, the known an-
ticancer peptide R7-KLA [12] and its C-terminus-R7 version KLA-R7
(Table 1) were synthesized by the same company. The chemicals
were purchased from Sigma Chemical Co. (St. Louis, MO, USA), and
valinomycin was purchased from Merck.
2.2. Isolation of rat liver mitochondria
Mitochondria from liver of male white rats (starved overnight)
were isolated by the method of differential centrifugation as de-
scribed earlier [25], following the principles outlined in the Guide
for the Care and Use of Laboratory Animals published by the USA
National Institutes of Health (NIH Publication No. 85-23, revised
1996) and approved by the Local Ethics Committee of the NationalTable 1
Polycationic peptides used in the work.
Name Amino acid sequence and peptide purity
P7-27 IYLATALAKWALKQGF (93%)
P7-26 IYLATALAKWALKQ (98%)
P7-4 RRRRRRR-GG-IYLATALAKWALKQGF (97%)
P7-5 IYLATALAKWALKQGF-GG-RRRRRRR (95%)
P7-6 RRRRRRR-GG-IYLATALAKWALKQ (94%)
P7-7 IYLATALAKWALKQ-GG-RRRRRRR (99%)
R7-KLA RRRRRRR-GG-KLAKLAKKLAKLAK (93%)
KLA-R7 KLAKLAKKLAKLAK-GG- RRRRRRR (95%)University of Colombia, Medellin Branch. The cooled liver was ho-
mogenized in medium containing 210 mM mannitol, 70 mM sucrose,
2.5 mM MgCl2, 1 mM EGTA–KOH, 0.3 mg/ml bovine serum albumin
(BSA, free fatty acid fraction V), and 10 mM HEPES–KOH, pH 7.2, at
0–4 °C. The homogenate was centrifuged at 600 ×g for 10 min at
0–4 °C and the obtained supernatant was centrifuged at 10 000 ×g for
10 min. The pellet was resuspended in the medium containing
210 mM mannitol, 70 mM sucrose, 50 μM EGTA–KOH, 0.3 mg/ml BSA
and 10 mM HEPES–KOH, pH 7.2, and mitochondria were sedimented
again at 10 000 ×g for 10 min. This stage of mitochondrial washing
was repeated and mitochondria were ﬁnally resuspended in 1 ml of
the same medium without BSA. The mitochondria obtained with this
procedure were characterized by the respiratory control ratio higher
than 4.5 using 5 mM succinate as substrate of oxidation.2.3. Isolation of red blood cells
RBCs were isolated from the blood of white rats as described in [26]
with slight modiﬁcations. Approximately 20% blood in medium com-
posed of 120 mM NaCl, 10 mM EDTA, 5 mM sodium citrate, and 5 mM
Tris–HCl, pH 7.4, was centrifuged at 3000 rpm for 10 min (Jouan centri-
fuge RM1812). The cells were washed three times in medium of
150 mM NaCl, 5 mM Tris–HCl, pH 7.4, and ﬁnally resuspended in the
same medium supplemented with 10 mM glucose to the ﬁnal hemato-
crit of 20%.2.4. Monitoring of the redox state of mitochondrial pyridine nucleotides
The level of reduced forms of mitochondrial pyridine nucleotides,
NAD(P)H, was monitored by ﬂuorescence at 450 nm using the Aminco-
Bowman Series 2 Luminescence Spectrometer as described earlier [27].
Mitochondria, at the ﬁnal concentration of 0.5 mg protein/ml, were
added to the incubation medium composed of 100 mM sucrose, 75 mM
KCl, 10 mM potassium phosphate, 50 μM EGTA, and 5 mM HEPES, pH
7.2 (SKPH medium). Where indicated, 5 mM succinate was added to
energize the mitochondria. The peptides were added at the ﬁnal concen-
trations of 2 μM or 5 μM, thus observing NAD(P)H oxidation induced by
the inner membrane permeabilization.2.5. Measuring of the ATPase activity of mitochondria
The ATPase activity of the mitochondria was registered as a pH
change resulting of protonic dissociation of the liberated inorganic
phosphate H2PO41− in the low buffered incubation medium composed
of 100 mM sucrose, 75 mMKCl, 4 mMHEPES–KOH, pH 7.4 (SKHmedi-
um). The pH trace was registered using the equipment composed of a
pH electrode, the ML165 pH Amp ampliﬁer and the ML866 PowerLab
4/30 high-performance data acquisition system (ADInstruments)
connected to the computer through the USB port. Mitochondria
(0.5 mg protein/ml) were added to the SKH medium supplemented
with 1 mM ATP. In some experiments, the SKH medium was also
supplemented with 1 mM MgCl2. To uncouple the mitochondria, and
thus to accelerate ATP hydrolysis, 2,4-dintrophenol (DNP) was added
to the ﬁnal concentration of 75 μM. DNP is a weak acid known to
cross biomembranes in protonated and un-protonated forms thus
strongly increasing membrane permeability to protons and abolishing
the proton electrochemical gradient across the inner mitochondrial
membrane that allows H+-ATPase functioning with the maximal rate.
At the end of pH registration, the pH value was shifted to an initial
state by appropriate addition of KOH, and 0.2 mM KH2PO4 was added
to demonstrate acidiﬁcation of the suspension resulting of protonic dis-
sociation of the appeared H2PO41− anions. The peptides were added to
ﬁnal concentrations of 2 μM, 3 μM or 5 μM.
Fig. 1. Estimation of the mitochondrial (A) and red blood cell (B) permeabilization by
the peptides P7-27 and P7-26. Mc - mitochondria (0.5 mg protein/ml) were added to
the SKPH medium; Suc — 2.5 mM potassium succinate; RBCs — red blood cells (0.2%
ﬁnal hematocrit) were added to the NH incubation medium supplemented with 2 μM
DisC3(5); Pep. — peptide addition; Val — 1 μM valinomycin; Panel A: Light dispersion —
upper traces, NAD(P)Hﬂuorescence— lower traces; Panel B: Light dispersion—upper traces,
DisC3(5) ﬂuorescence— lower traces.
1049V.V. Lemeshko / Biochimica et Biophysica Acta 1828 (2013) 1047–10562.6. Monitoring of the plasma membrane potential of red blood cells
The plasma membrane potential of RBCs was monitored using a
potential-sensitive ﬂuorescent probe DiSC3(5) [28]. Three different
incubation media were used: 1) the isotonic NaCl medium composed
of 150 mM NaCl, and 5 mM HEPES–NaOH, pH 7.4 (NH medium);
2) the isotonic NaCl–glucose medium composed of 63 mM NaCl,
125 mM glucose, and 5 mM HEPES–NaOH, pH 7.4 (NHG medium);
and 3) the isotonic NaCl–sucrose medium composed of 63 mM
NaCl, 125 mM sucrose, and 5 mM HEPES–NaOH, pH 7.4 (NHS medi-
um). The media were supplemented with 2 μMDiSC3(5) and the ﬂuo-
rescence intensity (648 nm excitation, 668 nm ﬂuorescence) was
registered using the Aminco-Bowman Series 2 Luminescence Spec-
trometer. RBCs were added at the ﬁnal hematocrit of 0.2%. To artiﬁ-
cially generate relatively high membrane potential, valinomycin was
added at the ﬁnal concentration of 1 μM. The peptides at the concen-
trations of 2 μM or 5 μM were added to the normal RBCs, or to the
RBCs pre-incubated with 1 μM valinomycin.
2.7. Monitoring of mitochondrial swelling or of shrinkage-swelling of red
blood cells
Mitochondrial swelling was monitored simultaneously with the
NAD(P)H ﬂuorescence using the standard quartz cuvette and a mod-
iﬁed cuvette holder [27] for the Aminco-Bowman Series 2 Spectrom-
eter. One of the two auxiliary channels allowed measurement of light
dispersion. The light, emitted by an infrared light-emitting diode
(920 nm) and dispersed at 90° in mitochondrial suspension, was
detected by an additionally mounted photodiode and ampliﬁer and
the ampliﬁer output signal was registered by the data acquisition sys-
tem of the spectrometer [27]. In the same manner, to observe RBC
shrinkage or swelling, light dispersion in the cell suspension (0.2%
ﬁnal hematocrit) was monitored simultaneously with the DiSC3(5)
ﬂuorescence as described previously [24].
The samples were constantly stirred with the magnetic stirrer and
maintained at the temperature of 30 °C.
2.8. Cell electroporation in the presence of peptides
RBCs (0.2% ﬁnal hematocrit) were added to the incubation medi-
um composed of 150 mM NaCl and 5 mM HEPES–NaOH, pH 7.4,
supplemented with 2 μM DiSC3(5). The peptides were added at the
ﬁnal concentration of 5 μM. The electrical pulses (5 pulses of 2500 V
and 10 μs duration, with a time interval of 500 ms between pulses)
were applied to the 1 ml suspension of RBCs in a typical 1 cm plastic
cuvette through the electrodes formed of several times curved plati-
num wires of 0.3 mm diameter. The pulses were generated by the
ECM-830 Electro Square Porator (Harvard Apparatus).
2.9. Estimation of cancer cell viability in the presence of peptides
Human leukemia Jurkat cells (5000 per well), or normal wild type
CHO cells, were plated in 96-well plates and incubated in the medium
RPMI 1649 (Sigma) supplemented with 5% fetal bovine serum (FBS)
at 37 °C in a 5% CO2 humidiﬁed atmosphere for 48 h. After that, cells
were treatedwith 5 μMpeptide (R7-KLA, KLA-7R, P7-4 or P7-5) and in-
cubated for 18 h. At the end of the treatment, cell viability was assessed
using MTT (3-(4, 5-dimethylahiazol-2-yl)-2, 5-diphenyltetrasodium
bromide) assay [29], by determining light absorbance by formazan in
an ELISA microplate reader at 570 nm wavelength.
2.10. Statistics
The data are presented as means and standard error of the mean
(S.E.M.). Analysis was performed with Student's t-test with pb0.05
considered as statistically signiﬁcant.3. Results
The peptides P7-27 and P7-26, that are the slightly modiﬁed short
fragments of the polycationic peptide BTM-P1, showed a remarkable
ability to induce oxidation of endogenous NAD(P)H of isolated rat
liver mitochondria energized under succinate oxidation (Fig 1A,
lower traces). The decrease in the steady state level of NAD(P)H ﬂuo-
rescence was accompanied with mitochondrial swelling (Fig. 1A,
upper traces). The activity of the longer peptide P7-27 was higher
than that of P7-26: two additions of 5 μM P7-26 caused the effects
comparable with those caused by only one addition of 5 μM P7-27
(Fig. 1A). Both peptides did not inﬂuence the plasma membrane po-
tential of the normal RBCs (Fig. 1B, lower traces, −Val) and even of
the valinomycin-treated RBCs having relatively high membrane po-
tential (Fig. 1B, lower traces, +Val). Under the same conditions, the
peptides did not change light dispersion of RBCs in the absence
(Fig. 1B, upper traces, −Val) or the presence of valinomycin
(Fig. 1B, upper traces, +Val).
The same peptides conjugated to the hepta-arginine fragment at
their N-termini (P7-4, P7-6) or at their C-termini (P7-5, P7-7), at
the peptide concentration of 2 μM, induced fast oxidation of endoge-
nous NAD(P)H in isolated rat liver mitochondria (Fig. 2A, lower traces
2), as well as caused mitochondrial swelling (Fig. 2A, upper traces 2).
Signiﬁcantly higher mitochondrial permeabilization was observed at
the peptide concentration of 5 μM (Fig. 2A, traces 5).
Fig. 2. Estimation of the mitochondrial (A) and red blood cell (B) permeabilization by the peptides P7-4, P7-5, P7-6 and P7-7. Mc - mitochondria (0.5 mg protein/ml) were added to
the SKPH medium; Suc – 2.5 mM potassium succinate; RBCs— red blood cells (0.2% ﬁnal hematocrit) were added to the NH incubation medium supplemented with 2 μMDisC3(5);
Val — 1 μM valinomycin; The peptides were added to the mitochondrial suspension at the ﬁnal concentrations of 2 μM or 5 μM, marked at curves by the numbers 2 and 5, respec-
tively, and to the RBC suspension at the concentration of 5 μM; Panels A: Light dispersion — upper traces, NAD(P)H ﬂuorescence — lower traces; Panels B: Light dispersion — upper
traces, DisC3(5) ﬂuorescence — lower traces.
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membrane potential of the normal RBCs monitored by the probe
DiSC3(5) (Fig. 2B, lower traces, −Val). As well, the peptides did not
change RBC light dispersion, as an indicator of cell volume changes
(Fig. 2B, upper traces, −Val).
Artiﬁcial generation of the plasmamembrane potential of relative-
ly high value in the presence of 1 μM valinomycin (near −85 mV
[24]), strongly potentiated the membrane permeabilization by the
designed peptides. It was revealed by rapid depolarization of the plas-
ma membrane just after the peptide additions (Fig. 2B, lower traces,
+Val), and by the cell swelling, according to the observed decrease
in light dispersion (Fig. 2B, upper traces, +Val). With this respect,
the peptides conjugated to the R7 vector at their C-terminus (P7-5,
P7-7) were more active than the corresponding peptides conjugated
at the N-terminus (P7-4 and P7-6). It should be also noted that the
longer peptides P7-4 and P7-5 were more active than the shorter
peptides P7-6 and P7-7, respectively (Fig. 2B, +Val).Fig. 3. Inﬂuence of the peptides P7-4, P7-5, P7-6 and P7-7 on the protonic ATPase activity of
supplemented with 1 mM ATP; were indicated, 1 mMMgCl2 (Mg) was added (+); DNP— 75
or 2 μM (C); The ﬁnal pH value was shifted (A) to the initial state by an appropriate KOH add
to protonic dissociation of H2PO41−. In the X axis, the scale of 2 mV corresponds to ΔpH=0The ability of the peptides to permeabilize the mitochondrial inner
membrane was also estimated by monitoring the ATPase activity of
isolated rat liver mitochondria (Fig. 3). As it is known, the rate of
ATP hydrolysis depends on the ionic conductivity of the inner mem-
brane. As a control, the addition of the uncoupler DNP increased
ATP hydrolysis for several times, and the ATPase activity was sensi-
tive to oligomycin, speciﬁc inhibitor of protonic ATPase (Fig. 3A).
The addition of KH2PO4 caused the medium acidiﬁcation resulting
from protonic dissociation of the appeared H2PO41− anions (Fig. 3A).
The addition of any of used peptides to ﬁnal concentration of 5 μM
did not signiﬁcantly increase the ATPase activity, and the subsequent
addition of DNP did not increase it (data not shown). The addition of
3 μM P7-4 or 3 μM P7-5 to the mitochondrial suspension in the SKH
medium supplemented with 1 mM ATP caused an increase in the
ATPase activity that was more signiﬁcant than that observed after
the addition of 3 μM peptides P7-6 or P7-7 (Fig. 3B). In these experi-
ments, the ATPase activity was further stimulated by DNP only in themitochondria. Mc—mitochondria (0.5 mg protein/ml) were added to the SKH medium
μM 2,4-dintrophenol; The peptides were added to the ﬁnal concentrations of 3 μM (B)
ition and then 0.2 mM KH2PO4 was added to demonstrate suspension acidiﬁcation due
.033.
Fig. 4. Inﬂuence of the peptides P7-4, P7-5, P7-6 and P7-7 on the plasma membrane
potential of red blood cells and on the cell shrinkage-swelling depending on the incu-
bation medium composition. RBCs — red blood cells (0.2% ﬁnal hematocrit) were
added to the NH (A), NHG (B) or NHS (C) incubation media; Light dispersion —
upper traces, DisC3(5) ﬂuorescence — lower traces.
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P7-4 or P7-5 (Fig. 3B).
The ATP hydrolysis requires magnesium ions. Thus, if the peptides
induce the release of magnesium from the mitochondrial matrix it
might lead to a decrease of the ATPase activity. That is why we next
compared the effects of 2 μM peptides in the absence and presence
of exogenous magnesium ions in the incubation medium. In the me-
dium without magnesium ions (Fig. 3C, (−)), the most signiﬁcant
stimulation of the ATPase activity was observed after the addition of
P7-5, in comparison with the peptides P7-4, P7-6 or P7-7 (Fig. 3C,
(−)). In the presence of 1 mM MgCl2 (Fig. 3C, (+)), an increase in
the ATPase activity by the peptides was more signiﬁcant than that ob-
served in the absence of magnesium (Fig. 3C, (−)). The highest stim-
ulation, up to the level of the DNP-stimulated activity, was observed
after the addition of P7-4 (Fig. 3C, (+)). In the case of other peptides,
the ATPase activity in the presence of 1 mM MgCl2 can be further in-
creased by DNP (Fig. 3C, (+)). Thus, in addition to an increase in the
protonic conductivity of the inner membrane, the peptides might
cause the depletion of the mitochondrial matrix magnesium ions
depending on the peptide concentration and the size of pores formed
by each of the peptides.
To further study the potential-dependent permeabilization of the
plasma membrane of RBCs, and to evaluate whether this perme-
abilization is caused by the peptide pore formation, or it is simply a
detergent-like effect of the peptides, we used glucose and sucrose as
osmotic protectors, replacing half of NaCl in isotonic NH incubation
media with corresponding sugars at respective concentration. The
high membrane potential was artiﬁcially generated adding 1 μM
valinomycin (Fig. 4). The peptide concentration in these experiments
was 2 μM (Fig. 4). The peptides P7-5 and P7-4 in the NH medium
demonstrated higher activity than P7-7 or P7-6, according to the ob-
served faster depolarization of the plasma membrane (Fig. 4A, lower
traces) and the faster light dispersion changes resulting from cell
swelling (Fig. 4A, upper traces). In the NHG (Fig. 4B, lower traces),
or in the NHS (Fig. 4C, lower traces) media, the rates of the membrane
depolarization by the peptides were signiﬁcantly higher than in the
NH medium (Fig. 4A, lower traces).
The light dispersion change of RBCs induced by the peptides in
sugar containing media was dependent on the type of sugar, glucose
(Fig. 4B, upper traces) or sucrose (Fig. 4C, upper traces). First of all,
very expressive cell shrinkage phase (light dispersion increase) was
observed just after the additions of each of the peptide, and the am-
plitudes of the shrinkage phase in the NHS medium (Fig. 4C, upper
traces) were almost twice of those observed in the NHG medium
(Fig. 4B, upper traces). The cell shrinkage was abruptly changed for
the cell swelling, and the slopes in the light dispersions decrease in
the NHS medium were at least only half of those observed in the
NHGmedium, for each of four studied peptides (Fig. 4C and B, respec-
tively, upper traces). In the sugar containing media, the peptide P7-5
caused faster cell swelling than corresponding shorter peptide P7-7,
as well as the peptide P7-4 was more active than the corresponding
shorter peptide P7-6 (Fig. 4B,C, upper traces).
As the plasma membrane permeabilization by the designed pep-
tides was strongly potentiated by the relatively high membrane po-
tential, generated in the presence of valinomycin (Fig. 2B, +Val),
we further studied the possibility of an increase of the membrane
permeabilization by the peptides by the application of external high
voltage electrical pulses to the suspension of normal RBCs, without
valinomycin (Fig. 5). The most active designed peptides P7-4 and
P7-5, according to the data shown in (Figs. 2–4, were studied with
this respect in comparison with the known anticancer peptide
R7-KLA [12]. The electrical pulses were applied to the RBC suspension
as shown in Fig. 5A through the platinum electrodes. The voltage, du-
ration and number of pulses were selected to not induce any signiﬁ-
cant permeabilization of RBCs monitored by the light dispersion
(Fig. 5A, upper traces) and by the plasma membrane potential(Fig. 5A, lower traces). An increase in the suspension temperature
just after the application of the pulses was less than 1 °C.
The presence of 5 μM R7-KLA in the RBC suspension caused an
increase in the effect of electrical pulses, according to the observed
light dispersion decrease and the membrane depolarization of RBCs
(Fig. 5B, upper and lower traces, respectively). Signiﬁcantly higher elec-
trical potentiation of RBC permeabilization was observed in the pres-
ence of the peptides P7-4 and P7-5, because faster decrease in light
dispersion (Fig. 5C,D, respectively, upper traces) and faster increase in
DiSC3(5) ﬂuorescence (Fig. 5C,D, respectively, lower traces) were ob-
served in both these cases just after the electrical discharge in compar-
ison with those observed in the presence of R7-KLA (Fig. 5B).
Finally, the inﬂuence of peptides P7-4 and P7-5 on the viability of
human leukemia Jurkat cells and of wild type normal CHO cells was
studied in comparison with the effects of the known anticancer pep-
tide R7-KLA [12], or of its KLA-R7 analog (Fig. 6). At the peptide con-
centration of 5 μM, the mortality of Jurkat cell was 18% (pb0.01) in
Fig. 5. Permeabilization of red blood cells by externally applied electrical pulses in the presence of the peptides R7-KLA, P7-4 and P7-5. RBCs— red blood cells (0.2% ﬁnal hematocrit)
were added to the NH incubation medium; Pulses — 5 pulses of 2500 V and of 10 μs duration each were applied using platinum electrodes (A) with a time interval of 500 ms
between pulses; Light dispersion — upper traces, DisC3(5) ﬂuorescence — lower traces.
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while higher mortalities, of 29% (pb0.01) and 31% (pb0.01) were de-
termined for the peptides P7-4 and P7-5, respectively (Fig. 6). No
statistically signiﬁcant decrease in the CHO cell viability was detected
in the presence of studied peptides (Fig. 6).Fig. 6. Viability of Jurkat and CHO cells treated with polycationic peptides. The peptides
R7-KLA, KLA-7R, P7-4 or P7-5 were added to the ﬁnal concentration of 5 μM. At the end
of the treatment, cell viability was assessed by a colorimetric MTT assay; The data are
the means±S.E.M., n=4–8. Cell viability (light absorbance at 570 nm).4. Discussion
Many antimicrobial polycationic peptides have been demonstrat-
ed to have anticancer activity in experiments with various cancer
cell lines and solid tumors [1–7,10–15]. The D and L forms of the arti-
ﬁcial polycationic KLA peptide, (KLAKLAK)2, have been used to design
highly effective anticancer peptides by conjugating them to cancer-
cell detecting [10,13,15] or penetrating [11,12,14] peptides, or to an-
tibodies that recognize malignant cells [16,17]. Particularly, the anti-
cancer activity of the artiﬁcial KLA peptide has been strongly
enhanced by its conjugation to the hepta-arginine cell-penetrating
peptide (R7 or r7) assuming that the hepta-arginine fragments in-
crease cell delivery of the KLA peptide to target and damage the mito-
chondria [12].
As we have earlier demonstrated, the D or L forms of the KLA pep-
tide conjugated to the R7 or r7 fragments, respectively [12] were
highly active in a direct permeabilization of isolated rat liver mito-
chondria, meanwhile the un-conjugated peptide (klaklak)2 at the
same concentration did not inﬂuence the state 4 respiration or the
level of NAD(P)H of energized mitochondria [20]. Taking into account
low activity of the peptide (klaklak)2 [12,20], we suggested [24] that
the anticancer peptides similar or even better than R7-KLA or r7-kla
might be designed on the basis of the highly active peptide BTM-P1derived from the protoxin Cry11Bb [21–24], or on the basis of shorter
Cry toxin fragments by conjugating them to cell delivery vectors, as
the R7 for example.
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the 16-mer (P7-27) and the 14-mer (P7-26) peptides with a minimal
modiﬁcation described above. These peptides, at the 5 μM and 10 μM
concentrations, respectively, induced endogenous NAD(P)H oxidation
and swelling of mitochondria (Fig. 1B). The most probable reason of
such inﬂuence is an increase in the ionic conductivity of the innermem-
brane. The same peptides at the concentration of 5 μM did not
permeabilize the RBCswith a normally lowplasmamembrane potential
(known to be near−10 mV) (Fig. 1B, ϑVal) or the RBCs with relatively
high membrane potential (near −85 mV [24]) generated in the pres-
ence of valinomycin (Fig. 1B, +Val).
The conjugation of the peptides P7-27 and P7-26 to the R7 fragment
at their N-termini (P7-4 and P7-6) or at the C-termini (P7-5 and P7-7),
respectively, through two glycine residues resulted in a signiﬁcant in-
crease of their ability to permeabilize isolated mitochondria (Fig. 2A)
and even the RBCs with artiﬁcially high membrane potential (Fig. 2B).
Interestingly, the C-terminus conjugated peptides P7-5 and P7-7 dem-
onstrated somewhat higher permeabilization of the mitochondria
(Fig. 2A) and of RBCs (Figs. 2B and 4) than the N-terminus conjugated
peptides P7-4 and P7-6, respectively.
An increase in the protonic ATPase activity of the mitochondria,
known to depend on the inner membrane potential, by the designed
peptides (Fig. 3) conﬁrmed the assumption that the peptides in-
creased the ionic conductivity of the inner membrane. The degree of
activation of ATP hydrolysis by 3 μM peptides in the absence of DNP
was higher for longer peptides P7-4 and P7-5. But in this case, no fur-
ther stimulation by DNP was detected. As the ATPase activity needs
magnesium ions, these data allowed suggestion that the 3 μM pep-
tides P7-4 and P7-5 induced magnesium release from the mitochon-
drial matrix. This was conﬁrmed by the addition of 1 mM MgCl2
after DNP that increased the ATPase activity (data not shown). In
the medium with 1 mM MgCl2 (Fig. 3C, curves marked with (+))
the longer peptides P7-4 and P7-5, even at the peptide concentration
of 2 μM, clearly demonstrated very expressive stimulation of the
ATPase activity, before the addition of DNP. The rate of the medium
acidiﬁcation after the addition of P7-4 was signiﬁcantly higher than
the dotted line control slope, or those observed in the presence of
other peptides. These data allowed suggestion that the peptide P7-4
generates larger ionic channels than other used peptides.
The assumption that ionic channels are generated by the designed
peptides is based on the experiments with osmotic protectors, glucose
and sucrose (Fig. 4). In the sugar containing media, the plasma mem-
brane depolarization of RBCs by all of the used peptideswas signiﬁcant-
ly faster than in the only NaCl medium (Fig. 4B,C in comparison with
Fig. 4A, lower traces). Because themembrane depolarizationwas higher
in the low ionic strength media (Fig. 4B,C), it might indicate that the
electrostatic interaction of the plasma membrane with the designed
polycationic peptides is essential for its permeabilization. On the other
hand, electrostatic interactions between polycationic peptides and rela-
tively high negative charge of the plasmamembrane of cancer cells, due
to the presence of phosphatidylserine in its outer leaﬂet, has been
reported as an important factor of selective killing of cancer cells by
known anticancer peptides [30 and references therein].
In sugar containing media, the RBC shrinkage phase was clearly ob-
served just after the peptide additions (Fig. 4B,C). This phasewas longer
in the sucrose containingmedium, and that is why it was more expres-
sive (Fig. 4C) in comparison with the shrinkage phase observed in the
glucose containing medium (Fig. 4B). Earlier, we have explained the
cell shrinkage phase, observed after the addition of BTM-P1 under
similar conditions [24] as a result of selective anionic permeability of
peptide pores at the initial stage of their formation. The RBC shrinkage
phase of the observed biphasic effects of the peptides P7-4, P7-5, P7-6
and P7-7 on cell light dispersion (Fig. 4) might be explained by KCl re-
lease from RBCs: due to a high permeability of the plasma membrane
to potassium ions in the presence of valinomycin and due to a selective-
ly high permeability to chloride ions, in comparison to sodium ions atthe initial stage of membrane permeabilization by the peptides. To be
able to observe the fast shrinkage phase, the permeability to chloride
ions at this stage should be at least signiﬁcantly higher than that to so-
dium ions. In the case of pure detergent-like effect of the peptides, only
the swelling phase should be observed, although an absence of the
shrinkage phase does not yet mean that the effect is detergent-like,
but that the permeability of the formed peptide pores is high to both
chloride and sodium ions. That is why, high amplitude swelling of
RBCs was observed at the second phase of the membrane perme-
abilization by the peptides (Fig. 4). The ﬁnal size of the formed peptide
pores seems to be of the order of magnitude of the sucrose hydrody-
namic radius, because the rates of the RBC swelling in the sucrose
containing medium were nearly half of those observed in the presence
of glucose for corresponding peptides, according to the slopes in the
light dispersion decrease (Fig. 4B,C).
The obtained data clearly demonstrated the potential-dependent
cell permeabilization by the designed peptides (Fig. 2B), like that ob-
served earlier for the potential-dependent permeabilization of mito-
chondria [20,21] and RBCs [20,21,23,24] by BTM-P1 and by the
anticancer peptides R7-KLA or r7-kla [20]. This potential-dependent
effect seems to be a very interesting technological aspect for local kill-
ing of solid tumors. On the other hand, it is impossible to locally use a
very toxic valinomycin, or similar ionophores, to generate adequate
membrane potentials. Instead, the locally applied external electrical
pulses of high voltage signiﬁcantly increased the efﬁciency of the
plasma membrane permeabilization by known anticancer peptide
R7-KLA and by the designed peptides P7-4 and P7-5 (Fig. 5). The
designed peptides were more efﬁcient in this respect than the pep-
tide R7-KLA. The obtained results also indicate that the polycationic
peptides might strongly increase the efﬁciency of the cell electropora-
tion. In addition, it seems to be very probable that the antimicrobial
activity of the known natural polycationic peptides might be signiﬁ-
cantly increased by the application of external electrical pulses.
It has been reported that mitochondrial and plasma membrane
potentials of cancer cells are typically higher in comparison with cor-
responding normal cells [31]. Thus, the local application of external
electrical pulses to solid tumors treated with the polycationic pep-
tides might additionally synergistically increase the selective antican-
cer effects of the designed peptides. The obtained results open the
perspective of development on new methods of combined “pep-
tide–electrical pulses” synergistic treatment of solid tumors with
the aim of their local destruction. The design of new polycationic pep-
tides with capability of the potential-dependent permeabilization of
biological membranes [20,21,23,24] might also contribute in the de-
velopment of such technology. The designed peptides P7-4 and
P7-5, which are longer than peptides P7-4 and P7-5, demonstrated
higher activity (Figs. 2–4). Thus, one can expect that conjugation of
even longer fragments of BTM-P1 to known cancer-cell detecting
[10,13,15] or penetrating [11,12,14] peptides might result in more ef-
ﬁcient anticancer drugs.
As a new drug development strategy, the electrical part of the com-
bined “peptide–electrical pulses” synergistic treatment could be real-
ized as described in [32–34]. The peptides could be directly injected
into a solid tumor [3,11,35–37] applying electrical pulses through a
needle or catheter to cause local irreversible cell electroporation [33,34]
additionally potentiated by the injected peptides. The method of irre-
versible cell electroporation is different from electrochemotherapy,
which combines cytotoxic nonpermeant drugs with reversible cell elec-
troporation to incorporate drugs into living cells, or from the method of
electrically induced thermal damage [34]. The possible electrode
constructions for electrical treatment of un-desirable tissues have
been recently published [32].
Even serum unstable all L-amino acid peptides seem to be possible
to use by their direct injections into solid tumors, as it has been dem-
onstrated for other peptides [11]. If some peptides appear in the
blood after their local injection, their binding or hydrolysis in serum
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hand, the peptides resistant to proteolysis have demonstrated signif-
icantly higher anticancer efﬁciency [35–37]. We have recently shown
a very similar membrane permeabilizing activities of L-amino acid
and D-amino acid forms of the peptide BTM-P1 [38]. These data
allow assumption that D-form peptides designed on the basis of frag-
ments of BTM-P1, or of other peptides derived from Cry11Bb protoxin
[38], will have higher proteolytic resistivity and will induce similar bi-
ological effects, like that shown for the peptides R7-KLA and r7-kla
[12,20].
The designed peptides P7-4 and P-7-5 demonstrated some prop-
erties (Figs. 2 and 4) very similar to those of anticancer peptides
R7-KLA or r7-kla [12] that we have reported earlier [20] and those
shown in Fig. 5. In addition, the peptides P7-4 and P-7-5 were more
active than the peptides R7-KLA or KLA-R7 in selective killing of
human leukemia Jurkat cells and were non-toxic for the normal
wild type CHO cells (Fig. 6). For other comparison, the well known
polycationic peptide mastoparan (commercially available), at the
peptide concentration of 3,6 μM, had almost no effect on the redox
state of mitochondrial pyridine nucleotides and did not induce swell-
ing of energized mitochondria under the same experimental condi-
tions (data not shown). Also, even at the concentration of 20 μM,
mastoparan did not induce depolarization or swelling of red blood
cells with artiﬁcially high membrane potential (data not shown).
The liposome encapsulated mastoparan has been shown to reveal
higher mitochondria-damaging activity in cancer cells in comparison
with the effect of the free peptide [39]. The described liposomal tech-
nology [39], in combination with the irreversible membrane electro-
poration (Fig. 5), could further increase anticancer efﬁciency and
selectivity of the designed peptides.
5. Conclusion
New polycationic peptides were designed on the basis of slightly
modiﬁed fragments of the peptide BTM-P1, derived from the Cry11Bb
protoxin, by their conjugation to the hepta-arginine cell-delivery vec-
tor. These peptides demonstrated many of the characteristics of the
known anticancer peptide R7-KLA. The capability of permeabilization
of the plasmamembrane by these peptides due to the formation of pep-
tide pores was increased by their electrostatic interactions with the
plasmamembrane and by an increase in the transmembrane potentials.
The selective anticancer activity of some of the designed peptides was
demonstrated using cancer Jurkat cells and normal CHO cells that
might be attributed to higher values of the surface [30] and membrane
potentials [31] in cancer cells. Additional studies are needed to conﬁrm
selective killing of cancer cells with the designed peptides. The efﬁcien-
cy of thedesigned peptides in the cell permeabilizationwas strongly en-
hanced by the application of external high voltage electrical pulses.
These results open the new avenues of development of new methods
of combined “peptide–electrical pulses” synergistic treatment of solid
tumors with the aim of their local destruction.
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